Fibromyalgia in children; diagnosis and treatment.
Fifteen children (16 years and younger, 10 females, 5 males, mean age 13 years) with juvenile primary fibromyalgia syndrome (JPFS) were seen in a private rheumatology practice over two years. This represented 45 percent of the total number of pediatric rheumatology patients. Symptoms included polymyalgias, polyarthralgias, nonrestorative sleep, difficulty concentrating in school and fatigue. Examination revealed typical tender points, absence of joint swelling, synovitis or nodules and absence of neurological findings. Dolorimetry was abnormal and standard laboratory tests were normal. Most of these patients (67 percent) had seen three or more doctors prior to their rheumatological evaluation and not (60 percent) were told they had juvenile chronic arthritis. Other diagnoses offered were "growing pains" (20 percent), hysteria (7 percent) and psychological problems (7 percent). None of the JPFS patients responded to salicylate or other anti-inflammatory medication. Most (73 percent) responded to cyclobenzaprine, mean dose 12.75 mg. (range 5-25 mg. qhs). JPFS is a very common pediatric rheumatologic problem and is confused with other disorders. Reassurance is very important in the therapy since many parents are fearful that their children may have a potentially crippling disorder. Medication, especially with tricyclics, moderate exercise and proper sleep are also mainstays of therapy.
Romano
T J
TJ
D000293:Adolescent; D000639:Amitriptyline / Q000008:administration & dosage / Q000031:analogs & derivatives; D000928:Antidepressive Agents / Q000008:administration & dosage; D002648:Child; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D005356:Fibromyalgia / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008297:Male; D009125:Muscle Relaxants, Central
D000928:Antidepressive Agents; D009125:Muscle Relaxants, Central; D000639:Amitriptyline; C004704:cyclobenzaprine